MDA touts fear of war with Hezbollah in fundraising campaign for new ambulances

Renee Ghert-Zand is the health reporter and a feature writer for The Times of Israel.

Illustrative: A Magen David Adom ambulance in central Israel, March 29, 2012. (Yaakov Naumi/Flash90)
Illustrative: A Magen David Adom ambulance in central Israel, March 29, 2012. (Yaakov Naumi/Flash90)

Magen David Adom announces an emergency campaign for 300 new ambulances to add to its current fleet of 1,400. This would be triple the number of ambulances the national emergency response organization usually adds to its fleet annually.

MDA is specifically focused on upping its number of mobile intensive care units (MICUs) and life support ambulances.

MDA says the exceptional campaign comes in response to growing concerns about the security of Israel’s northern border and the fear it could lead to an armed conflict.

“The number of ambulances we currently have has proven more than sufficient to address Israel’s daily needs and enable us to respond to Israel’s recent conflicts with Gaza-based terrorist groups, such as Hamas in 2021 and Islamic Jihad earlier this year,” said MDA director-general Eli Bin.“But we know that Hezbollah is a significantly better-armed enemy capable of striking virtually any part of Israel, and the devastation from a conflict with that group would inflict many more casualties,” he adds.

“And that means our ability to treat the wounded and transport them quickly to Israeli hospitals will be of paramount importance.”

More than 80% of MDA’s ambulances are produced through American Friends of Magen David Adom, MDA’s US-based fundraising affiliate, which has their ambulances manufactured in Elkhart, Indiana, before they’re shipped to Israel.

Never miss breaking news on Israel
Get notifications to stay updated
You're subscribed
Register for free
and continue reading
Registering also lets you comment on articles and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Please use the following structure:
Or Continue with
By registering you agree to the terms and conditions. Once registered, you’ll receive our Daily Edition email for free.
Register to continue
Or Continue with
Log in to continue
Sign in or Register
Or Continue with
check your email
Check your email
We sent an email to you at .
It has a link that will sign you in.